Brenus Pharma: $25 Million (Series A) Closed To Develop Cancer Vaccines
By Amit Chowdhry ● Sep 20, 2024
Brenus Pharma, a biotech company specializing in cancer vaccine development, announced the completion of a $25 million Series A funding round. This funding round was led by Angelor, an investment fund bringing together a cluster of investors from the Auvergne-Rhône-Alpes (AURA) region, including UI Investissement for the Fonds régional Avenir industrie Auvergne-Rhône-Alpes, Crédit Agricole Centre-France and Crédit Agricole Centre-Est, with two family offices. And the Belgian funds Noshaq and Investsud complete this significant deal. Together, they joined co-founder and lead investor Jacques Gardette (BIOJAG) and long-time investor Stéphane Legastelois (33 CALIFORNIE). Plus, Brenus Pharma has received non-dilutive funding from the French government and Bpifrance, as a beneficiary of the France 2030 call for projects.